This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

3 Key Points From Sarepta's Eteplirsen Study Update (And They're Positive)

Stocks in this article: SRPTRNAGSK

CAMBRIDGE, Mass. ( TheStreet) -- Three data points stand out for me from Sarepta Therapeutics (SRPT) eteplirsen update of the phase II study in Duchenne muscular dystrophy:

1. The six boys treated with 30 mg and 50 mg of eteplirsen from the beginning of the study have demonstrated remarkable stability in walking performance. After 96 weeks, the distance walked over six minutes has declined by just 6.3 meters compared to baseline. I'm using mean values.

The 96-week data are no fluke: Here are the changes in six-minute walk distance from baseline for the eteplirsen-treated boys from weeks 74, 84 and 96: -2.2 meters, -9.2 meters, -6.3 meters.

2. The four boys in the study initially treated with a placebo and switched to eteplirsen at week 25 (the crossover group) are also showing stable walking ability now that the effect of the drug has kicked in.

The best way to see the benefit of eteplirsen in these patients is to compare six-minute walk test performance between week 74 and week 96. At week 74, these four boys walked 62.4 meters less than at baseline. At week 96, the drop in walking distance was 67.7 meters. Basically the same.

Why skip the comparison with the week 84 measurement? Because one of the boys in the crossover group broke his ankle and was unable to perform the six-minute walk test for the week 84 analysis, thereby skewing the mean walking performance higher. The mean drop in walking distance at week 84 was -43.2 meters. The boy's broken ankle healed and he was able to perform the six-minute walk test at week 96, so comparing results to week 74 (before the fracture) is a fairer comparison.

Multiple studies have shown DMD boys lose muscle function and the ability to walk over time. Yet these 10 boys treated with eteplirsen are showing a continued stability in walking ability going on almost two years. This is a very impressive result. Two explanations: Eteplirsen is working or Sarepta lucked into selecting 10 boys for its phase II study who happened to have some of the slowest-progressing DMD in history.

3. Eteplirsen's safety record continues to sparkle, with no clinically significant adverse events related to drug, no treatment discontinuations, no hospitalizations. The risk-benefit balance for eteplirsen is helped considerably by what looks like very little of the former.

Sarepta will be presenting these 96-week data at the World Muscle Society meeting next month. This is the same venue where GlaxoSmithKline (GSK) and Prosensa (RNA) will present the data from the failed phase III study of drisapersen.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs